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Summary
Setting:  The  incidence  of  multi-  and  extensively  drug-resistant  TB  cases  is  increasing
in  many  countries.  Resistance  to  rifampicin  is  widely  considered  a  surrogate  marker
for  multiple  drug  resistant  TB.  No  efforts  have  been  made  to  identify  and  quantify
the  drug-resistant  genotypes  in  the  Syrian  and  Lebanese  communities.
Objective:  The  genotypic  characterization  of  rpo  B  mutations  in  the  rifampicin  drug-
resistance  region  (RRDR)  of  resistant  Mycobacterium  tuberculosis  isolates  in  Syrian
and  Lebanese  patients.
Design:  The  pyrosequencing  technique  was  applied  to  DNA  derived  from  the  M.
tuberculosis  isolates  of  56  patients.
Results:  RRDR  sequencing  identiﬁed  97  modiﬁed  codons  representing  35  different
mutations;  31  (34%)  of  the  97  modiﬁcations  were  novel  and  have  not  been  previously
reported.  The  changes  were  mostly  within  codons  531  (37/97:  38%),  533  (28/97:  29%)
and  526  (9/97:  9%).  Additionally,  30  (54%)  isolates  had  multiple  codon  changes.
Conclusion:  This  study  indicates  the  importance  of  the  RRDR  hotspot  region  for  the
detection  of  rifampicin  resistance  in  MTB  clinical  isolates  from  Syrian  and  Lebanese
patients.  However,  new  mutations  and  mutations  in  other  locations  within  the  RRDR
were  also  observed.  The  vast  majority  (95%)  of  the  studied  isolates  from  this  pool
of  patients  contained  mutations  in  codons  531  and/or  533.
©  2012  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Ltd.  All  rights  reserved.
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Introduction
Approximately  95%  of  all  of  tuberculosis  cases  occur
in developing  countries,  where  the  disease  has  typ-
ically remained  endemic  [1].  In  recent  years,  a
dramatic increase  in  the  number  of  cases  of  drug-
resistant  infections  has  occurred.  The  number  of
multi- and  extensively  drug-resistant  cases  (MDR,
XDR) was  estimated  to  be  approximately  440,000
in 2008,  with  150,000  deaths  [2].  MDR  TB  is thought
to emerge  in  patients  either  through  exogenous
infection by  resistant  strains  or  through  the  endoge-
nous emergence  of  mutations  due  to  suboptimal
treatment [3,4].  The  treatment  of  resistant  TB  is
medically  difﬁcult,  economically  expensive  and  has
adverse health  effects  for  patients  [5,6].  Despite
extensive  treatment  measures,  levels  of  mortality
are still  high.  However,  mortality  has  decreased  sig-
niﬁcantly [7]  in  recent  years  following  the  introduc-
tion  of  several  measures,  including  the  application
of molecular  diagnostic  techniques  [8],  strain  iden-
tiﬁcation [9]  and  the  investigation  of  transmission
[10,11].
The combination  of  rifampicin  and  isoniazid
is the  backbone  of  ﬁrst-line  and  short-course
chemotherapy.  Rifampicin,  a  macrocyclic  antibi-
otic, targets  mycobacterial  DNA-dependent  RNA
polymerase,  a  complex  oligomer  composed  of
four different  subunits  (,  ,  ′ and  ,  which
are encoded  by  rpo  A,  rpo  B,  rpo  C  and  rpo  D,
respectively). Rifampicin  binds  speciﬁcally  to
the rpo  B-expressed  subunit  and  suppresses  the
initiation  step  of  transcription  [12].  Resistance  to
rifampicin results  from  spontaneous  mutations,
which occur  at  a  rate  of  108. These  mutations
have been  widely  shown  to  localize  to  the  rpo  B
region,  primarily  in  codons  507—533.  This  81-bp
region is  called  the  RIF  resistance-determining
region (RRDR).  Resistance  to  rifampicin  is  largely
considered  a  surrogate  marker  for  MDR  TB  due
to its  association  with  other  drug  resistance
phenotypes  [13].
Pyrosequencing  technology  has  recently  been
used  to  characterize  the  genotypes  of  resistant
tuberculosis strains  [14—16].  Pyrosequencing  chem-
istry differs  in  several  aspects  from  standard
sequencing.  For  example,  ﬂuorochromes  and
radioactivity  are  not  used,  and  no  postreaction
step is  required  when  using  this  technique  [17].
The technology  enables  the  rapid  prediction  of
mutations  and  is  suitable  for  the  simultaneous
screening  of  short  sequences  in  large  numbers
of samples.  It  is  therefore  a  proven,  reliable
and high-throughput  assay  for  the  rapid  and  spe-
ciﬁc analysis  of  rifampicin-resistant  M.  tuberculosis
strains  [18].
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The  presence  of  drug-resistant  tuberculosis  in
yria and  Lebanon  is  known  [19].  However,  no
fforts  have  been  made  to  identify  and  quantify  the
rug-resistant  genotypes  in  this  community.  In  this
tudy, pyrosequencing  was  used  to  fully  character-
ze the  RRDR  mutations  prevalent  in  M.  tuberculosis
solates obtained  from  Syrian  and  Lebanese  patients
or the  ﬁrst  time.
aterials and methods
acterial strains
 total  of  56  clinical  rifampicin-resistant  Mycobac-
erium  tuberculosis  isolates  (resistant)  were
elected. These  clinical  isolates  were  provided  by
he Medical  Biotechnology  Section  of  the  National
ommission  for  Biotechnology  in  Syria  and  the
zm Center  for  Research  in  Biotechnology  and  Its
pplications  at  Lebanese  University.  The  isolates
ere  derived  from  45  Syrian,  7  Lebanese  and  4
raqi (living  in  Syria)  patient  samples  collected
etween July  2003  and  October  2005  from  all  Syr-
an and  Lebanese  provinces  (muhafazat)  [20,21].
he drug  resistance  pattern  of  the  Syrian  samples
as previously  established  according  to  the  recom-
endations  of  the  National  Committee  for  Clinical
aboratory  Standards  [21]  and  that  of  the  Lebanese
amples  was  also  previously  established  [20].  All
solates were  stored  at  −80 ◦C.  The  reference
train H37Rv  (ATCC  25177)  was  used  as  a  control
or the  wild-type  sequence.  The  research  was
pproved  by  the  responsible  institutional  ethics
ommittee.
NA extraction
NA  extraction  was  performed  with  maximum  pre-
autions under  a  biosafety  class  two  hood  according
o [20].  The  isolates  were  incubated  in  a water  bath
t 80 ◦C  for  approximately  30  min  to  kill  the  bacte-
ia and  then  centrifuged  for  10  min  at  8000  rpm.  TE
uffer containing  1%  Triton  X-100,  0.5%  Tween  20,
0 mM  Tris—HCl  pH  8.0  and  1  mM  EDTA  was  added
o the  pellet.  The  rest  of  the  procedure  was  per-
ormed  according  to  the  instructions  provided  with
he Qiagen  DNA  Blood  Mini  Kit  (Qiagen,  Germany)
ith one  minor  modiﬁcation:  the  incubation  period
t 37 ◦C was  2  h  instead  of  90  min.
CRhe  primers  used  to  amplify  and  sequence  the
ifampicin  resistance-determining  region  (RRDR)
ere synthesized  according  to  [22]  by Thermo
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cientiﬁc,  USA.  One  set  of  forward  and  reverse
rimers was  used  to  amplify  the  target  region.
he size  of  the  PCR  product  was  297  bp.  The  PCR
eaction  mixture  consisted  of  the  following:  1×
CR buffer,  2  mmol/L  MgCl2, 0.125  mol/L  of  each
ucleotide  (dATP,  dTTP,  dCTP,  and  dGTP),  and
.5 U  Taq  polymerase  (Sigma,  Germany)  in  a total
olume  of  50  L.  DNA  ampliﬁcation  was  performed
sing a  MyCycler  Bio-Rad  96-well  thermocycler
Bio-Rad,  Germany),  using  the  following  cycling
rogram:  initial  denaturation  and  enzyme  activa-
ion 95 ◦C  for  5  min;  40  cycles  of  three  steps  of
5 ◦C  for  30  s,  63 ◦C  for  30  s,  and  72 ◦C  for  30  s;  and
nal extension  at  72 ◦C  for  5  min.  PCR  products
5 L)  were  visualized  on  a  2%  agarose  gel  stained
ith ethidium  bromide  under  ultraviolet  light
sing the  ChemiDoc  program  (Bio-Rad,  Hercules,
A, USA).
yrosequencing
yrosequencing  was  performed  on  all  56  clinical
solates and  the  ATCC25177  reference  strain.  PCR
roducts  were  immobilized  on  streptavidin-coated
epharose  beads  (GE,  USA)  to  provide  single-
tranded DNA  templates.  The  beads  containing  the
mmobilized  templates  were  captured  on  a  ﬁlter
y vacuum  ﬁltration  and  were  washed  with  70%
thanol  for  5  s.  DNA  was  denatured  by  applying
.2 M  NaOH  for  10  s  and  then  washed  for  5  s with
0 mM  Tris-acetate,  pH  7.6.  The  beads  were  subse-
uently  transferred  to  a  96-well  plate  containing  an
nnealing solution  (38.4  L)  and  the  two  sequenc-
ng primers  (1.6  L)  (R1,  R2)  [22].  Two  separate
equencing primers  (R1,  R2)  (Thermo  Scientiﬁc,
SA) were  used  to  sequence  the  relatively  long
equence  (81  bp)  of  interest  within  the  ampliﬁed
297 bp)  product.  Pyrosequencing  was  performed
sing a  PyroMark  ID96  instrument,  which  is  an
utomated  PSQ  96  ID  system  (Qiagen,  Germany),
sing the  PSQ  Gold  96  SQA  reagent  kit  contain-
ng the  enzyme.  The  reaction  cascade  consisted
rimarily of  the  incorporation  of  nucleotides  into
he growing  DNA  chain,  culminating  in  the  pro-
uction  of  light.  The  pattern  of  light  emitted  in
elation to  the  nucleotide  dispensation  order  and
he number  of  nucleotides  incorporated  was  subse-
uently  illustrated  on  a  pyrogram.  The  mutations
ere detected  based  on  a  sequence  comparison
ith the  reference  strain  ATCC  25177.  An  inter-
al control  was  also  used  to  validate  the  results.
he BLAST  database  was  used  to  search  for  the
btained  sequences,  and  a  90%  minimal  similar-
ty match  with  the  M.  tuberculosis  genome  was
btained.
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esults
f  the  56  rifampicin-resistant  clinical  isolates  ana-
yzed, 45  were  from  Syrian  patients,  7  were  from
ebanese  (living  in  Lebanon)  patients,  and  four
ere from  Iraqi  citizens  (living  in  Syria).  The  pyro-
rams of  the  two  sequenced  rpoB  regions  (507—520
nd 521—533)  indicated  the  presence  of  97  modiﬁed
odons  (Table  1)  representing  35  different  codon
hanges  (Table  2).  All  resistant  strains  contained  at
east one  non-synonymous  codon  change  relative
o the  ATCC  reference  strain.  One  codon  change
as a consequence  of  a single  base  pair  deletion.
ive codon  changes  resulted  in  silent  mutations
hrough nucleotide  substitutions,  and  the  rest
esulted  in  missense  mutations.  All  silent  mutations
ere accompanied  by  non-silent  mutations.  Codon
hanges occurred  primarily  at  codons  531  (37/97:
8%), 533  (28/97:  29%)  and  526  (9/97:  9%);  only
ne, two  or  three  codon  changes  were  detected
n each  of  the  remaining  codons.  The  97  codon
hanges were  distributed  in  the  56  tested  isolates  as
ndicated in  Table  2.  Isolate  56(S)  had  the  greatest
umber  of  codon  changes  (5  codon  changes).  Eight
solates  had  three  codon  changes  (8/56:  14%),  and
wenty-one  isolates  had  two  codon  changes  (21/56:
8%) (Table  1).  The  isolates  with  multiple  codon
hanges  generally  included  changes  at  codon  533
26/30: 87%).  The  remaining  isolates  (26)  had  only
ne codon  change  (26/56:  46%),  most  commonly
t codon  531  (22/26:  85%)  (Table  1).  Changes  to
odons 531  and  533  occurred  in  53  patients  (53/56:
5%). The  mutation  S531  L  (TCG/TTG)  was  by  far
he most  frequent  (35  patients:  35/56:  63%),  fol-
owed by  L533R  (CTG/CGT)  (12  patients:  12/56:
1%), L533P  (CTG/CCG)  (7  patients:  7/56:  13%),
533R  (CTG/CGG)  (5  patients:  5/56:  9%)  and  H526D
CAC/GAC)  (4  patients:  4/56:  7%)  (Table  2).
Based on  the  information  provided  by  the  TB
rug resistance  mutation  database  [23],  which  lists
ll published  mutations  that  have  been  associated
ith  rifampicin  resistance,  15  of  the  30  different
issense codon  changes  obtained  (excluding  silent
odon changes)  represent  novel  codon  changes
50%). Most  of  the  novel  changes  were  located  in
odon 533.  Novel  codon  changes  represent  31  of  the
otal 92  codon  changes  (34%)  and  were  identiﬁed  in
0 of  the  56  patients  (54%)  (Table  2).  The  new  codon
hanges  at  positions  529  and  532  indicate  mutations
t new  locations.
The codon  changes  included  (43)  different  base
air changes  (nucleotide  position  or  base)  result-
ng in  a total  of  134  bp  changes  (63  transitions
nd 71  transversions).  Of  the  97  codon  changes,
8 (70%)  included  a  single  base  pair  change,  22
384  A.  Rahmo  et  al.
Table  1  The  patients  location  and  resistance  proﬁle  of  M.  tuberculosis  strains,  in  relation  to  obtained  rpoB  RRDR
codon  changes.
PCR number Location RIf INH Strp EMB Mutation 
ATCC 25177 U.S.A S S S S No mutation
68(S) Aleppo R R R R 531 TCG(S) TTG(L)                                                                                  533 CTG(L) GGC(G)
57(S) Aleppo R R R R 531 TCG(S) TTG(L) 
58(S) Aleppo R R R R 522 TCG(S) TTG(L) 
39(S) Aleppo R R R R 531 TCG(S) TTG(L)                                                                     533   CTG(L) CGT(R)
53(S) Aleppo R R R R 526 CAC(H) CAG(Q)            533 CTG(L) CCG(P) 
50(S) Aleppo R R R R 525    ACC(T) ATC(I) 531 TCG(S) TTG(L) 
28(S) Aleppo R R R R 526  CAC(H) CGC(R)  528 CGC(R) ACG(T) 533  CTG(L) CCG(P) 
29(S) Aleppo R R S R G deletion Position  15 533  CTG(L) CCG(P) 
31(S) Aleppo R R R R 531 TCG(S) TTG(L)                  533   CTG(L) CGT(R)
32(S) Aleppo R R R R 531 TCG(S) TTG(L)                  533   CTG(L) CGT(R)
13(S) Aleppo R R S S 531 TCG(S) TTG(L) 
77(S) Aleppo R R S R 531 TCG(S) TTG(L) 
14(S) Aleppo R R R R 526 CAC(H) TGC(C)        533     CTG(L) CGC(R)
83(S) Aleppo R S S S 526 CAC(H) GAC(D)       533 CTG(L) CGT(R)
108(S) Aleppo R R R R 531 TCG(S) TTG(L) 
104(S) Aleppo R R R R 531 TCG(S) TTG(L)                                                                                  533  CTG(L) CGG(R)
111(S) Aleppo R R R R 531 TCG(S) TTG(L) 
118(S) Aleppo R R R R 531 TCG(S) ATT(I)  533   CTG(L) CCG(P) 
11(S) Latakia R R R R 531 TCG(S) TTG(L) 
25(S) Latakia R R R S 526  CAC(H) CGC(R)  528 CGC(R) ACG(T) 533  CTG(L) CCG(P) 
110(S) Latakia R R R R 531 TCG(S) TTG(L) 
16(S) Deir ez Zor R R S R 531 TCG(S) TTG(L) 
19(S) Deir ez Zor R R R R 531 TCG(S) TTG(L) 
38(S) Deir ez Zor R R R S 526 CAC(H) CGC(R)    529     CGA(R) CAA(Q)       533 CTG(L) CGT(R)
20(S) Homs R R S R 517  CAG(Q) CCA(P)               531    TCG(S) TTG(L) 533 CTG(L) CGG(R)
66(S) Homs R S R S 531 TCG(S) TTG(L)
56(S) Homs R R R R 512 AGC(S) CTC(L) 513 CAA(Q) CCA(P)      524 TTG(L) CTC(L)  529 CGA(R) CGC(R)  533CTG(L ) CGT(R )
36(S) Hama R R R S 516 GAC(D) CTC(L)    517  CAG(Q) CAA(Q)  533  CTG(L) CGG(R)
64(S) Hama R R R R 531 TCG(S) TTG(L)                                                                                  53 3         CTG(L) CGT(R)
33(S) Damascus R R R S 531 TCG(S) TTG(L) 533     CTG(L) GCG(A)
49(S) Damascus R R R R 531 TCG(S) TTG(L)
115(S) Damascus R R R R 531 TCG(S) TTG(L)
82(S) Damascus R R R R 516 GAC(D) GTC(V)
96(S) Damascus R R R R 526 CAC(H) GAC(D      532 GCG(A) GGC(G)      533 CTG(L) CGG(R)
61(S) Damuscus R R R S 531 TCG(S) TTG(L) 
65(S) Damascus R R R R 531 TCG(S) TTG(L) 
69(S) Damascus R S R S 511 CTG(L) CCG(P)                                                                533    CTG(L) CGT(R)
51(S) Al Hasakah R R R R CAG(Q) AGA(R)                                                                    531 TCG(S) TTG(L) 
62(S) Al Hasakah R R S S 531 TCG(S) TTG(L)
79(S) Qamishli R R R R TCG(S) TTG(L)                         532 GCG A) CGC(R)     533 CTG(L) TGG(W)
106(S) AL Qamishli R R R R 513 CAA(Q) CAG(Q)       533  CTG(L) CCG(P) 
70(S) Quneitra R R R R 526  CAC(H) GAC(D)
9(S) Abu Kamal R R S S 531 TCG(S) TGC(C)
60(S) Rif Dimashq R R R R 512 AGC(S) ACC(T)  531  TCG(S) TTG(L)
42(S) Adra Prison R R S S 533 CTG(L) CGT(R)
40(I) Iraq R R R R 531 TCG(S) TTG(L) 
43(I) Iraq R R R R 531 TCG(S) TTG(L)                                                                     533   CTG(L) CGT(R)
97(I) Iraq R R R R 531 TCG(S) TTG(L)
44(I) Iraq R R S R 531 TCG(S) TTG(L) 
6(L) Dekweneh R R S S 512 AGC  (S) TCG(S)              513  CAA (Q )   CCA(P)  533 CTG(L) CCG(P) 
22(L) ALhamam AlAskari R R S S 526 CAC(H) GAC(D)         533  CTG(L) CGG(R)
26(L) MajdelAnjar R R S S 531 TCG(S) TTG(L)
50(L) HaretHreik R S R S 531 TCG(S) TTG(L)
58(L) Kafaat R R R S 522 TCG(S) TTG(L) 533      CTG(L)  CGT(R)
60(L) Sayfeh R R S S 531 TCG(S) TTG(L) 
(S)  
ance
D
T
t
a
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i
S61(L) Mazraa R R R S 531 TCG
S: Syrian sample, L: Lebanese sample, I: Iraqi national; R: resist
(23%)  included  two,  and  7 (7%)  included  three  base
pair changes.  It  appears  that  18  codon  changes
involved 2  bp  inversions  (Table  1).  Most  of  the  mis-
sense codon  changes  represented  non-conservative
amino acid  replacements.  The  most  frequent  codon
changes  at  position  531  involve  a  switch  from  a
polar to  a  hydrophobic  residue  (S/L,  I),  while  the
changes  at  position  533  resulted  in  a  switch  from  a
hydrophobic  to  a  charged  residue  (L/R).  Several  of
the codon  changes  involved  mutations  to  proline,  a
known secondary  structure  disrupter  (Table  2).
r
H
tTTG(L)                                                                        533  CTG(L)  CGT(R)
, S: sensitivity; (amino acid one letter symbol).
iscussion
he  fact  that  all  isolates  with  phenotypic  resis-
ance to  rifampicin  used  in  this  study  exhibited
mino acid  changes  in  the  RRDR  region  demon-
trates the  importance  of  the  RRDR  hotspot  region
n the  resistance  of  clinical  TB  isolates  in  Syria.
everal studies  have  indicated  that  this  region  is
esponsible  for  90—95%  of  RIF-resistance  cases  [24].
owever,  many  new  mutations  were  identiﬁed  in
his study,  and  some  were  found  at  new  locations
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Table  2  The  distribution  of  various  codon  changes  among  isolates.
Codon  Codon  change  Patients  (S:  Syrian,  L:  Lebanese,  I:  Iraqi)
511  #  G  deletion
Position  15  29(S)
511  CTG(L)  →  CCG(P)  69(S)
512  si AGC(S)  →  TCG(S)  6(L)
512 #AGC(S)  →  CTC(L) 56(S)
512 AGC(S)  →  ACC(T) 60(S)
513 CAA  (Q)  →  CCA(P) 6(L)  56(S)
513  si CAA(Q)  →  CAG(Q) 106(S)
516  #GAC(D)  →  CTC(L)  36(S)
516  GAC(D)  →  GTC(V)  82(S)
517  si  CAG(Q)  →  CAA(Q)  36(S)
517  #CAG(Q)  →  AGA(R)  51(S)
517  CAG(Q)  →  CCA(P)  20(S)
522  TCG(S)  →  TTG(L)  58(L)  58(S)
524  si  TTG(L)  →  CTC(L)  56(S)
525  ACC(T)  →  ATC(I)  50(S)
526  CAC(H)  →  GAC(D)  70(S)  83  (S)  96  (S)  22(L)
526  CAC(H)  →  CGC(R)  25(S)  28(S)  38(S)
526 CAC(H)  →  CAG(Q) 53(S)
526 CAC(H)  →  TGC(C) 14(S)
528 #CGC(R)  →  ACG(T) 25(S)  28(S)
529 #CGA(R)  →  CAA(Q) 38(S)
529  si CGA(R)  →  CGC(R) 56(S)
531 TCG(S)  →  TTG(L) 26)L)  60(L)  61(L)  11(S)  13(S)  16(S)  19(S)  20(S)
31(S)  32(S)  33(S)  39(S)  40(I)  43(I)  44(I)  49(S)
50(S)  51(S)  57(S)  60(S)  61(S)  62(S)  64(S)  65(S)
66(S)  68(S)  77(S)  79(S)  97(I)  104(S)  108(S)
110(S)  111(S)  115(S)  50(L)
531  #TCG(S)  →  TGC(C)  9  (S)
531  #TCG(S)  →  ATT(I)  118(S)
532  #GCG)A)  →  CGC(R)  79(S)
532  #GCG(A)  →  GGC(G)  96(S)
533  #CTG(L)  →  CGC(R)  14(S)
533  #CTG(L)  →  CGG(R) 22(L)  20(S)  36(S)  96(S)  104(S)
533  #CTG(L)  →  CGT(R)  58(L)  61(L)  31(S)  32(S)  38(S)  39(S)  42(S)  43(I)
56(S)  64(S)  69(S)  83(S)
533  CTG(L)  →  CCG(P)  6(L)  25(S)  28(S)  29(S)  53(S)  106(S)  118(S)
533  #CTG(L)  →  GCG(A)  33(S)
533  #CTG(L)  →  GGC(G)  68(S)
533  #CTG(L)  →  TGG(W)  79(S)
Total  different  codon
changes:  35
Total  codon  changes:  97
w
p
5
c
l
t
o
i
o
p
5
d
w
a
p
[
iSi: silent mutation; #: new mutation.
The bold signiﬁes novel mutations as the sign # does.
ithin  the  RRDR.  Notably,  the  vast  majority  of
atients  (95%)  had  mutations  in  codons  531  and/or
33. This  could  greatly  reduce  the  expense  and
omplexity  of  future  early  detection  efforts  in  the
ocal patient  pool.
Earlier  studies  [24]  have  asserted  the  impor-
ance of  codon  positions  526  and  531  to  the
bserved resistance.  This  is  true  also  in  neighbor-
ng countries,  such  as  Turkey.  A  similar  earlier  study
f the  hotspot  rpo  B  locus  in  isolates  from  Turkish
atients primarily  identiﬁed  mutations  at  codons
b
t
e31  (56.1%)  and  526  (19.5%)  [25].  Eight  of  the  14
ifferent  mutations  observed  in  that  study  (57%)
ere present  in  our  patient  pool.  The  present  study
lso emphasizes  the  frequency  of  codon  changes  at
osition 533.  In  clear  contrast  to  previous  reports
26,27],  the  majority  of  isolates  in  this  study  exhib-
ted more  than  one  codon  change  (2—5).Many  codon  changes  involved  more  than  one
ase pair  change.  A  signiﬁcant  portion  appeared
o involve  a  two-base  pair  inversion,  while  oth-
rs were  likely  to  involve  multiple  base  pair
[[
[
[
[
[
[386  
substitutions  through  point  mutations.  The  high
GC/AT ratio  may  contribute  mechanistically  to  the
mutability  of  this  hot  spot  region.
Noticeably,  codon  changes  at  533  were  accom-
panied by  other  codon  changes  in  almost  all  of  the
isolates (with  one  exception).  Changes  at  this  posi-
tion are  reported  to  result  in  variable  resistance;
therefore, additive  resistance  could  be  a  signiﬁcant
resistance  mechanism  in  these  strains.
Some  rpoB  codon  changes  have  been  shown
to cause  cross-resistance  to  antibiotics  other
than rifampicin  in  M.  tuberculosis  isolates.  Codon
changes  at  513,  526,  and  531  are  associated  with
high-level  resistance  to  rifampicin  and  rifabutin.
Codon changes  at  514,  515,  516,  522,  and  533
have been  reported  to  cause  rifampicin  resistance
concomitant with  susceptibility  or  low  resistance
to rifabutin  [28].  Thus,  depending  on  the  geno-
type, the  use  and  disuse  of  other  antibiotics  (e.g.,
in second-line  Tb  drug  treatment)  can  be  sug-
gested  [28].  However,  this  conclusion  depends  on
the assessment  of  the  novel  codon  changes  and  the
additive effects  of  multiple  codon  changes.
Despite  the  dominance  of  isolates  with  the  geno-
type  S531  L,  the  diversity  of  the  isolate  genotypes
is striking.  With  respect  to  the  18  isolates  obtained
from  Aleppo,  6  had  the  S531  L genotype,  while  the
rest (12)  had  9  different  genotypes.  This  diversity
is consistent  with  the  lower  exogenous  transmission
of resistant  strains  in  Syria,  which  was  suggested  by
a previous  strain  genotyping  study  [21].
One drawback  of  this  study  is  the  small  number
of Lebanese  samples,  which  cannot  be  considered
representative  of  the  rpo  B  pool  of  mutations  in
Lebanon.  Future  comparisons  with  other  neighbor-
ing countries  await  more  extensive  local  studies  of
the rpoB  sequence.
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